Literature DB >> 25017418

ALK expression is absent in pancreatic ductal adenocarcinoma.

Steffen Ormanns1, Gerald Assmann, Simone Reu, Eike Gallmeier, Dominik C Bader, Axel Kleespies, Michael Haas, Stephan Kruger, Volker Heinemann, Thomas Kirchner, Stefan Boeck.   

Abstract

PURPOSE: It has not yet been clearly defined whether anaplastic lymphoma kinase (ALK) expression can be detected in pancreatic ductal adenocarcinoma (PDAC).
METHODS: Within a retrospective study, archival PDAC surgical specimens were screened for ALK expression in tumor and normal tissue by immunohistochemistry (IHC) with the use of a specific ALK detection kit on a tissue microarray (TMA).
RESULTS: PDAC tumor tissue was available from 99 resected cases: fifty-eight out of 99 patients (59 %) had nodal-positive disease, and 80 patients (81 %) had pT3 tumors. Forty-nine patients underwent R0 resection, and in 48 cases, resection status was classified R1. Regarding ALK expression, five cases showed faint immunoreactivity on TMA, which was negative on whole mount sections. All other 94 cases showed no ALK expression.
CONCLUSION: In 99 PDAC cases, no ALK expression was detected by IHC; ALK thus may not serve as a relevant drug target in PDAC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25017418     DOI: 10.1007/s00432-014-1774-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  17 in total

1.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

2.  Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

Authors:  Christina I Selinger; Toni-Maree Rogers; Prudence A Russell; Sandra O'Toole; Poyee Yip; Gavin M Wright; Zoe Wainer; Lisa G Horvath; Michael Boyer; Brian McCaughan; Maija Rj Kohonen-Corish; Stephen Fox; Wendy A Cooper; Benjamin Solomon
Journal:  Mod Pathol       Date:  2013-06-07       Impact factor: 7.842

3.  Rare ALK expression but no ALK rearrangement in pancreatic ductal adenocarcinoma and neuroendocrine tumors.

Authors:  Rondell P D Graham; Andre M Oliveira; Lizhi Zhang
Journal:  Pancreas       Date:  2013-08       Impact factor: 3.327

4.  Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

Authors:  Gilda da Cunha Santos; Neesha Dhani; Dongsheng Tu; Kayu Chin; Olga Ludkovski; Suzanne Kamel-Reid; Jeremy Squire; Wendy Parulekar; Malcolm J Moore; Ming Sound Tsao
Journal:  Cancer       Date:  2010-09-07       Impact factor: 6.860

Review 5.  Targeting oncogenic ALK: a promising strategy for cancer treatment.

Authors:  Enrique Grande; María-Victoria Bolós; Edurne Arriola
Journal:  Mol Cancer Ther       Date:  2011-04       Impact factor: 6.261

6.  ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH.

Authors:  Eugen C Minca; Bryce P Portier; Zhen Wang; Christopher Lanigan; Carol F Farver; Yan Feng; Patrick C Ma; Valeria A Arrossi; Nathan A Pennell; Raymond R Tubbs
Journal:  J Mol Diagn       Date:  2013-03-13       Impact factor: 5.568

Review 7.  ALK inhibitors in the treatment of advanced NSCLC.

Authors:  Cesare Gridelli; Solange Peters; Assunta Sgambato; Francesca Casaluce; Alex A Adjei; Fortunato Ciardiello
Journal:  Cancer Treat Rev       Date:  2013-08-07       Impact factor: 12.111

8.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

9.  EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.

Authors:  Y Fukuyoshi; H Inoue; Y Kita; T Utsunomiya; T Ishida; M Mori
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

10.  ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.

Authors:  Yuan Li; Yunjian Pan; Rui Wang; Yihua Sun; Haichuan Hu; Xuxia Shen; Yongming Lu; Lei Shen; Xiongzeng Zhu; Haiquan Chen
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more
  2 in total

Review 1.  [Personalized cancer medicine : Biomarkers for molecular therapy stratification in pancreatic carcinoma].

Authors:  S Ormanns
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

2.  Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.

Authors:  Sebastian R Nielsen; Jan E Strøbech; Edward R Horton; Rene Jackstadt; Anu Laitala; Marina C Bravo; Giorgia Maltese; Adina R D Jensen; Raphael Reuten; Maria Rafaeva; Saadia A Karim; Chang-Il Hwang; Luis Arnes; David A Tuveson; Owen J Sansom; Jennifer P Morton; Janine T Erler
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.